Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Marks & Spencer raises retail staff pay with £95m investment

(Sharecast News) - Marks & Spencer announced on Wednesday that it is making its biggest-ever investment in pay for retail staff to lift minimum wages to at least the Real Living Wage. The high street stalwart said in a statement that it is pumping £95m into UK retail pay to raise wages for customer assistants to "at least £12.60 an hour", from the current minimum of £12 an hour.

For team support managers, the hourly rate will rise to £13.65 from £13.05.

Meanwhile, customer assistants working at the company's London stores will see their hourly rate will rise to £13.85 from £13.15, while London-based team support managers will see an increase to £14.90 from £14.20.

The new rates will affect the roughly 50,000 customer assistants in the UK from 1 April.

M&S has raised its standard hourly rate by over 26% since 2022, having invested around £285m.

The retailer said it comes "despite new cost pressures from the government", with higher employer contributions to National Insurance set to kick in next month.

"Following the Government's recent increases in tax and national insurance contributions, it's no secret that M&S and indeed the entire retail sector has some significant cost headwinds to face into in the new financial year," said chief executive Stuart Machin.

"However, I have always believed that we should not allow these headwinds to impact our hourly paid colleagues, which is why today, for the third year in a row, we are making a record investment in our retail pay offer."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.